Multiple myeloma with high adenosine deaminase expression

DOI IR
  • NAKAMURA Shingen
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • MIKI Hirokazu
    Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan
  • IWASA Masami
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • IKEGAME Akishige
    Division of Medical Technology, Tokushima University Hospital, Tokushima, Japan
  • MARUHASHI Tomoko
    Department of Internal Medicine, Local Incorporated Administrative Agency Tokushima prefecture Naruto hospital, Tokushima, Japan
  • SUMITANI Ryohei
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • UEMURA Munenori
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • TAKAHASHI Mamiko
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • ODA Asuka
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • FUJII Shiro
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • KAGAWA Kumiko
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
  • ABE Masahiro
    Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan

Search this article

Abstract

<p>A 50-year-old man with immunoglobulin A type multiple myeloma (MM) was referred to our hospital after bortezomib therapy. He had high alkaline phosphatase and lactate dehydrogenase levels. Computed tomography showed osteolytic and osteoblastic bone lesions. Response to salvage chemotherapy was temporary, and he developed a right pleural effusion with high adenosine deaminase (ADA) levels. He died from bleeding associated with a pelvic bone fracture 9 months later. ADA mRNA expression and ADA secretion of the MM cells from the patient were higher than those from myeloma cell lines tested. Clinical relevance of high ADA expression in MM cells is warranted.</p>

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top